Page 72 - book

Product List IRANIAN PHARMACEUTICAL COMPANIES DIRECTORY

Type Product Dosage form Strength Indication Status

-Metastatic Breast Cancer
Lyophilized powder
Antineoplas- Paclinab (Albumin (as nanoparticles) 100 mg - Locally advanced or metastatic Non- Marketed
Small Cell Lung Cancer
tic agent bound paclitaxel) for suspension for
infusion - Metastatic Adenocarcinoma of the
Pancreas
Hormone Receptor (HR) positive, hu-
75 mg,
Antineoplas- Palbocap (Palbo- Capsules, for oral 100 mg, man epidermal growth factor receptor 2 Marketed
tic agent ciclib) use (HER2)-negative advanced or metastatic
125 mg
breast cancer
Chelating SYPPER (Trientine Capsule, for oral use 250 mg Wilson’s disease Marketed
agent HCl)
Lyophilized Powder 100 mg/ HER2-positive, metastatic breast cancer Registered with
Antineoplas- PADYNEX (Trastu- for concentrate for vial, 160 adjuvant therapy for residual disease in Limited distribu-
tic agent zumab Emtansine)
solution for infusion mg/vial HER2-positive early breast cancer tion
Registered with
Antineoplas- FOLYPRA (Pralatrex- Solution for intrave- 20 mg/ml Relapsed or refractory peripheral T-cell Limited distribu-
tic agent ate) nous injection lymphoma (PTCL)
tion
Lyophilized powder
Opioid EXOPIO (Naltrex- (as microspheres) - Treatment of alcohol dependence
receptor one extended-re- for suspension 380 mg - Prevention of relapse to opioid depen- Marketed
antagonist lease) for intramuscular dence
injection
Treatment of coronavirus disease 2019
(COVID-19) in adults and adolescents
Antiviral Remdesivir-ND Concentrate for 100 (12 years of age and older with body Marketed
Agent (Remdesivir) Solution for Infusion mg/20 mL weight at least 40 kg) with pneumonia
requiring supplemental oxygen
Corticoste- DEPOSTIVA (Triam- Lyophilized powder, 32 mg/5 Management of osteoarthritis pain of Marketed
cinolone acetonide injectable suspen-
roid mL the knee
extended-release) sion
Antihaemor- TPORAL (Eltrom- F.C. Tablet, for oral 25 mg, 50 Thrombopoietin receptor agonist Marketed
rhagics bopag olamine) use mg
Lyophilized powder
Antineoplas- Bortezomib-ND for Solution for 1 mg, 3.5 Proteasome inhibitor Marketed
tic agent (Bortezomib) mg
Injection
Antineoplas- Osimertinib- ND F.C. Tablet, for oral 40 mg, 80 Tyrosine kinase inhibitor Marketed
(Osimertinib
tic agent use mg
mesylate)
Pemetrexed-ND Powder for Concen-
-Antineo- (Pemetrexed diso- trate for Solution for 100 mg, Inhibits thymidylate transferase and Marketed
plastic agent 500 mg other folate-dependent enzymes
dium) Infusion
71